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Abstract CD8+ T cells recognizing minor histocompati-
bility antigens (MiHA) on solid tumor cells may mediate
eVective graft-versus-tumor (GVT) reactivity after alloge-
neic stem cell transplantation (SCT). Previously, we identi-
Wed LRH-1 as a hematopoietic-restricted MiHA encoded
by the P2X5 gene. Here, we report that LRH-1 is aberrantly
expressed on solid tumor cells. P2X5 mRNA expression is
demonstrated in a signiWcant portion of solid tumor cell
lines, including renal cell carcinoma (RCC), melanoma,
colorectal carcinoma, brain cancer and breast cancer.
Importantly, P2X5 gene expression was also detected in a
subset of primary solid tumor specimens derived from
RCC, brain cancer and breast cancer patients. Furthermore,
P2X5 expressing solid tumor cells can be eVectively tar-
geted by LRH-1-speciWc cytotoxic T lymphocytes under
inXammatory conditions. The expression of HLA-B7 and
CD54 on tumor cells increases upon cytokine stimulation
resulting in improved T cell activation as observed by
higher levels of degranulation and enhanced tumor cell
lysis. Overall, hematopoietic-restricted MiHA LRH-1 is
aberrantly expressed on solid tumor cells and may be used
as target in GVT-speciWc immunotherapy after SCT.
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Introduction
Allogeneic hematopoietic stem cell transplantation (SCT)
is an established curative treatment for patients with hema-
tological malignancies and an experimental approach for
solid tumors [3, 13]. Initial evidence for a beneWcial graft-
versus-tumor (GVT) eVect in solid tumors was demon-
strated in patients with metastatic breast cancer [10, 27].
Subsequent studies investigated the feasibility and safety of
nonmyeloablative stem cell transplantation (NST) in order
to reduce treatment-related toxicity [5, 6, 21, 22]. In these
nonmyeloablative regimens, immunosuppression allows
donor engraftment but frequently results in mixed chime-
rism. Conversion to complete donor chimerism can be
achieved by withdrawal of immunosuppression and adop-
tive immunotherapy by donor lymphocyte infusion (DLI)
[4]. Several studies have demonstrated that treatment with
NST and DLI can induce tumor regressions in some types
of metastatic solid tumors [5, 6, 21, 22]. However, this
GVT eVect is often accompanied by severe graft-versus-
host disease (GVHD), which results in considerable
morbidity and mortality. Furthermore, most responses in
patients with metastatic solid tumors are partial and the rate
I. M. Overes and T. Henriëtte Levenga contributed equally to this 
study. P. H. De Mulder deceased in April 2007.
I. M. Overes · J. C. M. Vos · A. van Horssen-Zoetbrood · 
R. van der Voort · T. M. de Witte · H. Dolstra (&)
Central Hematology Laboratory, 
Nijmegen Centre for Molecular Life Sciences, 
Radboud University Nijmegen Medical Centre, 
Geert Grooteplein 8, P.O. Box 9101, 
6500 HB Nijmegen, The Netherlands
e-mail: h.dolstra@chl.umcn.nl
T. Henriëtte Levenga · T. M. de Witte
Department of Hematology, 
Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands
P. H. De Mulder
Department of Medical Oncology, 
Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands123
430 Cancer Immunol Immunother (2009) 58:429–439of complete remissions is limited. Therefore, further
development of SCT-based allogeneic immunotherapy for
solid tumors requires novel strategies to selectively boost
GVT immunity in the absence of GVHD.
The GVT eVect is predominantly mediated by donor-
derived T cells recognizing minor histocompatibility anti-
gens (MiHA) on malignant cells of the recipient. However,
ubiquitously expressed MiHA often induce GVHD, result-
ing in T cell-mediated destruction of normal tissues such as
skin, liver and gut. Therefore, it would be highly beneWcial
to direct donor T cell immunity towards MiHA that are
selectively co-expressed on hematopoietic cells and solid
tumor cells by vaccination or T cell therapy. Only a few
hematopoietic-restricted MiHA have been described that
are aberrantly expressed on solid tumors, including HA-1
[12, 16], ECGF-1 [23] and BCL2A1 [2, 24]. Therefore, it is
important to enlarge the panel of MiHA that can be used for
immunotherapy of solid tumors.
Previously, we have identiWed a hematopoietic-restricted
MiHA, designated LRH-1, which elicits an HLA-B7-
restricted cytotoxic T cell (CTL) response in leukemia
patients treated with DLI [7]. LRH-1 is encoded by the P2X5
gene and results from a single nucleotide frameshift poly-
morphism between recipient and donor cells. P2X5 expres-
sion has been demonstrated in myeloid progenitor cells and
peripheral blood T cells, B cells and NK cells as well as lym-
phoid organs [7]. Furthermore, P2X5 is expressed in a broad
range of lymphoid malignancies resulting in eVective LRH-
1-speciWc CTL-mediated lysis [20]. In contrast, P2X5
mRNA was not detected in primary cell cultures of non-
hematopoietic origin such as Wbroblasts, keratinocytes, mela-
nocytes and proximal tubule renal epithelial cells. Moreover,
P2X5 expression is not detected in prominent GVHD target
tissues such as skin, liver, colon and small intestine [7].
Here, we investigated whether the P2X5-encoded LRH-
1 epitope is expressed on solid tumors in addition to hema-
topoietic cells. We revealed that P2X5 mRNA is aberrantly
expressed in several types of solid tumors, including renal
cell carcinoma (RCC), melanoma, colorectal carcinoma,
brain cancer and breast cancer. Furthermore, we demon-
strated that P2X5-expressing solid tumor cell lines are
eYciently recognized and lysed by LRH-1-speciWc CTL.
These Wndings illustrate that LRH-1 can be used as target in
the development of MiHA-speciWc immunotherapy after
allogeneic SCT for metastatic solid tumors.
Materials and methods
Cell lines
The following solid tumor cell lines were used: RCC cell
lines SKRC 1, 7, 10, 12, 17, 18, 24, 33, 35, 52, and 59
were kindly provided by Dr. E. Oosterwijk (Department of
Urology, Radboud University Nijmegen Medical Centre
(RUNMC), Nijmegen, The Netherlands); melanoma cell
lines BLM, FM3, MEL397, and 518A2 were kindly pro-
vided by Dr. J. de Vries (Department of Tumor Immunol-
ogy, RUNMC, Nijmegen, The Netherlands); colorectal
carcinoma cell lines HT29, KATO3, HCT15, HCT116,
RKO, SW480, and SW620, and brain cancer cell lines BE(-
2)C, CHP212, DAOY, D283med, PFSK-1, SK-N-DZ, SK-
N-SH, SW1088, TE671, and U-87MG, and breast cancer
cell lines BT549, CAMA-1, MCF-7, MDA-MB-134VI,
MDA-MB-157, MDA-MB-175VII, MDA-MB-361, MDA-
MB-436, SK-BR-3, and T47D were kindly provided by Dr.
M. Schutte (Department of Medical Oncology, Josephine
Nefkens Institute, Erasmus University Medical Center, Rot-
terdam, The Netherlands). Skin-derived Wbroblasts were
kindly provided by S. van der Velde-Visser (Department of
Human Genetics, RUNMC, Nijmegen, The Netherlands). All
cell lines were cultured in Iscove’s modiWed Dulbecco’s
medium (IMDM) (Invitrogen, Carlsbad, California) supple-
mented with 10% fetal calf serum (FCS). Prior to analysis
solid tumor cell lines and Wbroblasts and keratinocytes were
cultured for 4 days in the absence or presence of inXamma-
tory cytokines IFN (100 U/ml) and TNF (10 ng/ml).
Primary tumor specimens
mRNA from 42 primary solid tumor specimens was used
for gene expression analysis. mRNA from 15 RCC sam-
ples, containing ¸80% tumor cells, was kindly provided
by Dr. E. Oosterwijk, (Department of Urology, RUNMC,
Nijmegen, The Netherlands), mRNA from 13 brain tumors
(4 medulla blastomas and 9 gliomas), containing ¸80%
tumor cells [14], was kindly provided by H. Jacobs
(Department of Pediatric Oncology, RUNMC, Nijmegen,
The Netherlands), and mRNA from 14 breast cancer
samples, containing 70–90% tumor cells [11], was kindly
provided by Dr. P. Span (Department of Chemical Endocri-
nology, RUNMC, Nijmegen, The Netherlands).
CTL culture
CTL were cultured as previously described [7, 20]. CTL
RP1 recognizes the 9-mer epitope TPNQRQNVC in the
context of HLA-B*0702. The HLA-B7-alloreactive CTL
clone KOR18 was kindly provided by Prof. E. Goulmy
(Department of Immunohematology, Leiden University
Medical Center, The Netherlands).
ImmunoXuorescence analysis
Tumor cell lines were studied for surface expression of
HLA-B7 and adhesion molecules by Xow cytometry. Cells123
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icon Millipore, Billerica, MA), anti-CD54 (clone 84H10;
Immunotech Beckman Coulter, Fullerton, CA), or anti-
CD58 (clone AICD58; Immunotech) and analyzed using
the Coulter FC500 Xow cytometer (Beckman Coulter,
Fullerton, CA). The fold induction in surface expression
was calculated by dividing the mean Xuorescence intensity
(MFI) of cytokine-stimulated cells by the MFI of unstimu-
lated cells.
Real-time quantitative RT-PCR of the P2X5 gene
P2X5 mRNA and CD45 mRNA expression were deter-
mined as previously described [7, 20]. The hydroxy-
methylbilane synthase (HMBS) housekeeping gene was
used to normalize expression. The following gene-speciWc
primers and Taqman probes were used: P2X5; P2X5-F 5-T
CCTGGCGTACCTGGTCGT-3, P2X5-R 5-CTTCATTC




AAA-3 and CD45-probe 5-(TET)-ATTTCCGTGTAAA
AGATC-(TAMRA)-3, and HMBS; HMBS-F 5-GGCAAT
GCGGCTGCAA-3, HMBS-R 5-GGGTACCCACGCGA
ATCAC-3 and HMBS-probe 5-(VIC)-CTCATCTTTGG
GCTGTTTTCTTCCGCC-(TAMRA)-3. P2X5 mRNA
expression was quantiWed by determining calibration func-
tions using JVM-2 as reference cell line. The level of P2X5
expression was calculated relative to the P2X5 expression
in the JVM-2 cell line, which is susceptible to lysis by
LRH-1-speciWc CTL.
P2X5 genotyping
P2X5 genotyping was performed as previously described
[20]. The following gene-speciWc primers and Taqman
probes were used: P2X5; P2X5-EXON3-F 5-CCAAATC
AAACCTCAGCACAGAC-3, P2X5-EXON3-R 5-CTCA
GTGCCTCTCTGGTTCCTTA-3, P2X5 5C allele-speciWc
probe 5-(FAM)-ATTGTGACCCCCAACCA-(MGB)-3
and P2X5 4C allele-speciWc probe 5-(VIC)-TGTGACCC
CAACCAG-(MGB)-3.
Flow cytometry-based cytotoxicity studies
Flow cytometry-based cytotoxicity assays were performed
as previously described with minor adaptations [15, 20].
Characteristics of the solid tumor cell lines used as targets
are described in Table 1. Endogenous HLA-B7+ cell lines
were labeled with 2.5 M carboxyXuorescein diacetate suc-
cimidyl ester (CFSE; Molecular Probes Europe, Leiden,
The Netherlands). Alternatively, endogenously HLA-B7¡
cell lines were retrovirally transduced with LZRS-HLA-
B*0702-IRES-EGFP as previously described [7] and used
as targets without CFSE-labeling. Target cells (1 £ 104)
were co-cultured with unlabelled eVector cells (3 £ 104) at
an E:T ratio of 3:1 in a total volume of 200 l IMDM/10%
FCS containing 25 U/ml IL-2 in 96-wells Xat-bottom
plates. For measurement of T cell degranulation at day 1,
anti-CD107a (BD Biosciences, Franklin Lakes, NJ) was
added to the T cells prior to co-culture. After 1–3 days of
co-culture, cells were harvested and 7-amino-actinomycin
D (7AAD) was added. Numbers of viable target cells were
quantiWed by Xow cytometry.
Table 1 Characteristics of the solid tumor cell lines used in Xow cytometry-based cytotoxicity assays
N/A indicates not applicable, N/D indicates not determined
a P2X5 genotyping was performed by PCR ampliWcation of genomic DNA using allele-speciWc probes
b Normalized P2X5 mRNA expression was determined by real-time quantitative RT-PCR and expressed relative to the expression level in the B-
cell prolymphocytic leukemia (B-PLL) JVM-2 cell line
c InXammatory conditions are mimicked by tumor cell culture in the presence of inXammatory cytokines IFN and TNF for 4 days
d HLA-B7¡ cell lines were transduced with HLA-B7. Expression of HLA-B7 was measured by Xow cytometry and expressed as mean Xuores-
cence intensity (MFI). The MFI of the isotype control varied between 0.24 and 0.34
Cell line Tumor type P2X5 
genotypea
P2X5 mRNA expressionb HLA-B7 expressiond
Control IFN + TNFc Type Control IFN + TNFc
DAOY Brain tumor C/C 0.88 0.70 Endogenous 3.4 10.4
BLM Melanoma C/C 1.54 1.58 Endogenous 1.5 5.1
SKRC33 RCC C/– 0.60 0.96 Endogenous 3.9 15.1
SKRC18 RCC C/– 0.50 0.42 Ectopic 6.5 6.8
FM3 Melanoma –/– 0.66 0.61 Ectopic N/D N/D
LRH-1+ LCL N/A C/– 2.8 N/D Endogenous N/D N/D
LRH-1¡ LCL N/A –/– 2.5 N/D Endogenous N/D N/D123
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Expression of the P2X5 gene in solid tumor cells
To deWne whether non-hematopoietic malignancies could
be targets for LRH-1-speciWc CTL, we have analyzed P2X5
mRNA expression in solid tumor cell lines and primary
tumor specimens by real-time quantitative RT-PCR. We
tested a panel of 42 cell lines of various histological origin
including RCC, melanoma, colorectal carcinoma, brain
cancer and breast cancer. In addition, we analyzed primary
tumor specimens derived from 15 patients with RCC, 13
patients with brain cancer, and 14 patients with breast can-
cer. Previously, we found that EBV-transformed lympho-
blastoid cell lines (EBV-LCL) that have a mean expression
level of 2.7 compared with the reference B cell line JVM-2
are signiWcantly recognized by LRH-1-speciWc CTL [7]. In
contrast, monocytes and Wbroblasts with a mean P2X5
mRNA expression level of 0.28 and 0.10, respectively, are
not susceptible to LRH-1 CTL-mediated lysis. Based on
these observations, we used a cut-oV P2X5 mRNA level of
0.4 to distinguish P2X5-positive from P2X5-negative cell
types [7]. Interestingly, signiWcant P2X5 mRNA expression
was observed in 13 out of 42 (31%) solid tumor cell lines,
covering all cancer types studied (Fig. 1). We detected
P2X5 transcripts in 3 out of 11 RCC cell lines, in 2 out of 4
melanoma cell lines, in 4 out of 7 colorectal carcinoma cell
lines, in 3 out of 10 brain cancer cell lines, and in 1 out of
10 breast cancer cell lines. In the primary tumor samples
studied, we detected P2X5 mRNA levels of ¸0.4 in 8 out
of 15 RCC samples, 4 out of 13 brain cancer samples, and
4 out of 14 breast cancer samples (Table 2). To determine
whether P2X5 expression could be due to the presence of
hematopoietic cells, we also analyzed expression of CD45.
We calculated the ratio of P2X5/CD45 and considered that
P2X5 expression in samples with a ratio <1.0 probably
resulted from inWltrated hematopoietic cells. We observed
that in at least 3 out of 15 RCC samples, 2 out of 13 brain
cancer samples, and 2 out of 14 breast cancer samples
P2X5 mRNA levels of ¸0.4 with a P2X5/CD45 ratio of
>1.0 could be detected (Table 2). These Wndings corrobo-
rate with our results observed in solid tumor cell lines.
Together, these data show that the LRH-1-encoding P2X5
gene is signiWcantly expressed in a subset of solid tumors.
P2X5-expressing solid tumor cells are eYciently lysed 
by LRH-1-speciWc CTL
Target cell recognition by LRH-1-speciWc CTL is con-
trolled by a single cytosine deletion polymorphism
(rs5818907) in exon 3 of the P2X5 gene [7]. Therefore,
P2X5-expressing tumor cell lines were genotyped at
rs5818907 by allele-speciWc PCR. Based on this P2X5
genotyping analysis, we have selected the homozygous (C/
C genotype) or heterozygous (C/– genotype) LRH-1+ tumor
cell lines DAOY (brain cancer), BLM (melanoma),
SKRC33 and SKRC18 (both RCC) as targets for LRH-1-
speciWc CTL in cytotoxicity assays (Table 1). For these
experiments, we used a Xow cytometry-based cytotoxicity
assay, which facilitates determination of target cell prolifer-
Fig. 1 P2X5 gene expression in 
solid tumor cells. P2X5 mRNA 
expression was determined by 
real-time quantitative RT-PCR 
in 42 solid tumor cell lines. Cell 
lines from the following tumor 
types were analyzed: renal cell 
carcinoma (RCC; n = 11), 
melanoma (n = 4), colorectal 
carcinoma (n = 7), brain cancer 
(n = 10), and breast cancer 
(n = 10). Expression is shown 
relative to the P2X5 expression 
measured in reference B-cell 
line JVM-2, which is susceptible 
to lysis by LRH-1-speciWc CTL. 
The housekeeping gene HMBS 
was used for normalization. 
Solid tumor cell lines with P2X5 
expression higher than 0.4 were 
considered positive and potential 
targets for LRH-1-speciWc CTL, 
based on previous expression 
and recognition studies. This 
arbitrary threshold is indicated 



























































































































































































Cancer Immunol Immunother (2009) 58:429–439 433ation and death by both rapid and more slowly T cell eVec-
tor mechanisms [15]. Moreover, the addition of low-dose
IL-2 to the co-cultures prolongs CTL survival, which
allows continuous exposure and serial killing of tumor cells
by the CTL. Using this in vitro assay, we have demon-
strated that LRH-1-speciWc CTL eYciently lysed LRH-1+
EBV-LCL, whereas no cytotoxicity was observed against
LRH-1¡ EBV-LCL (Fig. 2a). Interestingly, regarding the
solid tumor cell lines, we observed that the LRH-1+ brain
cancer cell line DAOY could also be eYciently targeted by
LRH-1-speciWc CTL (Fig. 2b). Microscopic analysis con-
Wrmed high susceptibility of DAOY for cytotoxicity by
LRH-1-speciWc CTL (Fig. 2c). LRH-1+ melanoma cell line
BLM, which has a relative high P2X5 mRNA expression
level of 1.5, was less eYciently lysed by LRH-1-speciWc
CTL (Fig. 3a). However, stimulation of BLM with inXam-
matory cytokines IFN and TNF strongly enhanced sus-
ceptibility to lysis by LRH-1-speciWc CTL. Similar results
were obtained with LRH-1+ RCC cell lines. Lysis of RCC
cell line SKRC33 was signiWcantly enhanced upon pre-
incubation with IFN and TNF (Fig. 4a). In contrast,
LRH-1 CTL-mediated lysis of SKRC18 could not be
enhanced by inXammatory cytokines, which might be asso-
ciated with the relative low P2X5 mRNA expression of
0.42 (Fig. 4b). In addition, SKRC 18 did not endogenously
express HLA-B7 and HLA-B7 expression could not be
upregulated by cytokine pre-incubation (Fig. 5a). The
observation that exogenous loading of SKRC18 with LRH-
1 peptide resulted in complete lysis indicated that the low
responsiveness is most likely caused by low epitope density
at the cell surface. No cytotoxicity was observed against
HLA-B7-transduced LRH-1¡ FM3 melanoma cells either
unstimulated or pre-stimulated with inXammatory cyto-
kines (Fig. 3b). Allo-HLA-B7-speciWc CTL lysed both
LRH-1+ and LRH-1¡ solid tumor cell lines (Figs. 2, 3, 4).
Taken together, these data demonstrate that LRH-1+ solid
tumor cell lines which have suYcient P2X5 expression lev-
els can be eVectively targeted by LRH-1 CTL, especially
under inXammatory conditions.
Enhanced tumor cell lysis under inXammatory conditions 
is associated with higher levels of degranulation 
by LRH-1-speciWc CTL
To determine whether up-regulation of P2X5 mRNA could
explain the increased tumor cell lysis upon stimulation with
inXammatory cytokines, we measured P2X5 mRNA levels
of untreated and cytokine-treated solid tumor cell lines by
real-time quantitative RT-PCR. However, no signiWcant
change in P2X5 mRNA expression was observed in the
Table 2 P2X5 and CD45 gene expression in primary solid tumor cells
Normalized P2X5 and CD45 mRNA expression was determined by
real-time quantitative RT-PCR and expressed relative to the expres-
sion level in the B-cell prolymphocytic leukemia (B-PLL) JVM-2 cell
line








1 3.84 6.51 0.6
2 3.03 1.32 2.3
3 2.30 1.49 1.5
4 1.50 4.59 0.3
5 1.34 8.47 0.2
6 1.26 1.29 1.0
7 0.47 0.78 0.6
8 0.40 2.22 0.2
9 0.34 1.01 0.3
10 0.33 2.01 0.2
11 0.22 1.98 0.1
12 0.17 1.17 0.1
13 0.16 2.45 0.1
14 0.11 1.92 0.1
15 0.09 0.67 0.1
Brain cancer 1 1.11 1.56 0.7
2 1.06 0.36 2.9
3 0.70 0.24 2.9
4 0.35 1.57 0.2
5 0.23 0.90 0.3
6 0.19 0.07 2.7
7 0.13 0.07 1.7
8 0.10 1.95 0.1
9 0.08 1.09 0.1
10 0.02 0.16 0.1
11 0.02 0.79 <0.1
12 0.02 1.34 <0.1
13 0.01 0.09 0.2
Breast cancer 1 1.48 0.74 2.0
2 0.54 0.40 1.4
3 0.52 1.32 0.4
4 0.38 0.49 0.8
5 0.13 0.12 1.1
6 0.08 0.69 0.1
7 0.06 0.49 0.1
8 0.06 0.45 0.1
9 0.03 0.58 0.1
10 0.03 0.36 0.1
11 0.02 0.39 0.1
12 0.02 0.40 <0.1
13 0.01 0.17 0.1
14 0.01 0.17 0.1123
434 Cancer Immunol Immunother (2009) 58:429–439presence of cytokines (Table 1). In addition, we observed
that P2X5 expression remains undetectable in keratinocytes
and very low in skin-derived Wbroblasts in the presence of
inXammatory cytokines (Table 3). On the other hand, Xow-
cytometric analysis showed that expression of adhesion
molecule CD54 (ICAM-1) increased 3.0-fold to 7.4-fold in
solid tumor cell lines upon cytokine stimulation, whereas
no signiWcant changes were observed in expression of
CD58 (LFA-3) (Fig. 5a). Furthermore, cytokine stimulation
resulted in more than threefold increase of HLA-B7 expres-
sion in cell lines which are endogenously HLA-B7+ (Fig. 5a).
Next, we determined whether up-regulation of HLA-B7
and CD54 expression on solid tumor cells resulted in
increased activation of LRH-1-speciWc CTL. Therefore, we
measured CTL degranulation by expression of CD107a on
the cell surface after 1 day of co-incubation with solid
tumor cell lines and control EBV-LCL. The proportion of
LRH-1-speciWc CTL expressing CD107a following co-culture
Fig. 2 Cytotoxicity against solid tumor cell lines was determined after
incubation with LRH-1-speciWc CTL (Wlled up triangle), HLA-B7-
speciWc CTL (Wlled inverted triangle; positive control) or medium only
(Wlled diamond). Survival of unstimulated and cytokine-stimulated tar-
get cells in the absence or presence of CTL at an E:T ratio of 3:1 is
shown of an LRH-1+ and LRH-1¡ EBV-LCL (a) and of LRH-1+ brain
tumor cell line DAOY (b). P2X5 mRNA expression is shown between
parentheses. Data are depicted as mean § SD of triplicate wells. c
Microscopic analysis of cytokine-stimulated DAOY cells at 40 h of co-
culture with CTL or medium













































































Cancer Immunol Immunother (2009) 58:429–439 435with LRH-1-positive and -negative EBV-LCL was 66 and
14%, respectively (Fig. 5b). Consistent with the cytotoxic-
ity data observed in the Xow cytometry-based cytotoxicity
assays, the percentage CD107a+ CTL was high after
co-culture with LRH-1+ solid tumor cell lines DAOY
(32%) and SKRC33 (39%), but relatively low for BLM
(8%) and SKRC18 (2%). In addition, when co-cultured
with tumor cells pre-treated with inXammatory cytokines
the proportion of CD107a+ LRH-1-speciWc CTL signiW-
cantly increased to 60% for DAOY and 32% for BLM.
SKRC18 tumor cells stimulated 25% of LRH-1-speciWc
CTL to degranulate only after pre-treatment with cytokines
and loading with LRH-1 peptide. Elevated levels of CTL
degranulation correlated with better lysis of tumor cells in
cytotoxicity assays.
Together, these results suggest that inXammatory cyto-
kines improve the formation of an immunological synapse
by up-regulation of MHC class I and CD54, resulting in
higher levels of granule exocytosis and enhanced CTL
reactivity. The increased activation of CTL upon cytokine
stimulation results in improved tumor cell lysis as observed
in cytotoxicity assays.
Discussion
MiHA are considered to play an important role in GVT
reactivity after allogeneic SCT for solid tumors [2, 24,
26]. Especially MiHA with tumor-restricted tissue distri-
bution are promising targets to boost GVT reactivity
selectively without enhancing GVHD. For further devel-
opment of tumor-speciWc immunotherapy it is important
to enlarge the spectrum of molecularly identiWed MiHA
which are selectively expressed in solid tumors and possi-
bly hematopoietic cells. Here, we analyzed the expression
of the LRH-1-encoding P2X5 gene in a large panel of
solid tumor cell lines and primary tumor specimens using
real-time quantitative RT-PCR. SigniWcant P2X5 mRNA
levels were detected in 31% of the solid tumor cell lines
tested, including RCC, melanoma, colorectal carcinoma,
Fig. 3 Cytotoxicity against LRH-1+ melanoma cell line BLM (a) and
LRH-1¡ melanoma cell line FM3 (b) was determined after incubation
with LRH-1-speciWc CTL (Wlled up triangle), HLA-B7-speciWc CTL
(Wlled inverted triangle; positive control) or medium only (Wlled dia-
mond). Survival of unstimulated and cytokine-stimulated target cells in
the absence or presence of CTL at an E:T ratio of 3:1 is shown. P2X5
mRNA expression is shown between parentheses. Data are depicted as

























































































436 Cancer Immunol Immunother (2009) 58:429–439brain cancer and breast cancer. Primary samples could be
tested for RCC, brain cancer and breast cancer and
showed similar numbers of P2X5 positive samples per
tumor type. Therefore, LRH-1 belongs to the few hemato-
poietic-restricted MiHA that additionally show an aber-
rant expression on solid tumor cells. Expression on solid
tumor cells was previously demonstrated for MiHA HA-1
[12, 16], ECGF-1 [23], and BCL2A1 [2, 24]. Enlargement
of the panel of MiHA is essential for development of
eVective post-transplantation immunotherapy. We and
others observed that only a part of the tested cell lines and
patient samples are positive for MiHA expressed on solid
tumors. In addition, the applicability of MiHA is depen-
dent on the frequencies of the MiHA and presenting-HLA
Fig. 4 Cytotoxicity against LRH-1+ RCC cell lines SKRC33 (a) and
SKRC18 (b) was determined after incubation with LRH-1-speciWc
CTL (Wlled up triangle), HLA-B7-speciWc CTL (Wlled inverted trian-
gle; positive control) or medium only (Wlled diamond). Survival of
unstimulated and cytokine-stimulated target cells in the absence or
presence of CTL at an E:T ratio of 3:1 is shown. P2X5 mRNA expres-
sion is shown between parentheses. Data are depicted as mean § SD
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Cancer Immunol Immunother (2009) 58:429–439 437phenotypes. Therefore, identiWcation of additional MiHA
is essential for further improvement of tumor-speciWc
immunotherapy.
All currently molecularly described MiHA are identiWed
from patients with hematological malignancies or aplastic
anemia. Molecular identiWcation of MiHA from patients
transplanted for a metastatic solid tumor has not yet been
reported. However, Tykodi et al. [26] have described CD8+
CTL clones recognizing MiHA on RCC tumor cells that
have been isolated from patients transplanted for metastatic
RCC. They demonstrated that CTL clones from two diVer-
ent patients recognize the same MiHA. Though the gene
encoding this MiHA was linked to chromosome 19q, they
did not describe the molecular characterization of this
MiHA yet. Dorrschuck et al. [8] obtained RCC-reactive
CTL from co-cultures of mixed lymphocytes with tumor
cells. Using microcapillary liquid chromatography and
MALDI-TOF spectrometry they identiWed an HLA-
A*0301-associated non-polymorphic peptide, encoded by
the ubiquitously expressed Eps-15 homology domain-con-
taining 2 (EHD2) gene. Since EHD2 is broadly expressed
in malignant and normal tissues, antigens encoded by this
gene are no candidates for tumor-speciWc immunotherapy.
Fig. 5 a The expression of 
adhesion and MHC molecules in 
epithelial cancer cell lines. 
Surface expression of HLA-B7, 
CD54 (ICAM-1) and CD58 
(LFA-3) was determined by Xow 
cytometry. Prior to analysis cells 
were cultured for 4 days in the 
absence or presence of inXam-
matory cytokines IFN and 
TNF. Data are depicted as fold 
induction of the mean Xuores-
cence intensity (MFI) upon cyto-
kine stimulation. b Cytokine 
stimulation of cancer cells re-
sults in improved degranulation 
of CTL. Anti-CD107-antibody 
was added to the co-cultures of 
Xow cytometry-based cytotoxic-
ity assays. Degranulation of 
LRH-1-speciWc CTL was mea-
sured after 1 day of co-culture 
with solid tumor cell lines and 
control EBV-LCL. Data are 
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Table 3 P2X5 gene expression in keratinocytes and Wbroblasts
a Normalized P2X5 mRNA expression was determined by real-time
quantitative RT-PCR and expressed relative to the expression level in
the B-cell prolymphocytic leukemia (B-PLL) JVM-2 cell line
b InXammatory conditions are mimicked by cell culture in the pres-
ence of inXammatory cytokines IFN and TNF for 4 days prior to
RNA isolation
Tissue type Sample P2X5 mRNA expressiona
Control IFN + TNFb
Keratinocytes 1 0.01 0.01
2 0.01 0.01
3 0.01 0.01
Fibroblasts 1 0.04 0.06
2 0.14 0.33
3 0.19 0.08123
438 Cancer Immunol Immunother (2009) 58:429–439Recently, the Wrst RCC-associated antigen, CT-RCC1,
was identiWed using allogeneic T cells isolated from a
patient treated with allogeneic SCT for metastatic RCC
[25]. The antigenic CT-RCC region is a part of the human
endogenous retrovirus (HERV) type E locus. Interestingly,
HERV-E is selectively expressed on RCC cells, but not on
normal tissues including renal cells. However, CT-RCC is
presented by HLA-A11 which is only present in a minority
of the population. Thus, until more solid tumor-associated
antigens or solid tumor-speciWc MiHA are identiWed, hema-
topoietic restricted MiHA co-expressed on solid tumors
represent very useful targets for immunotherapy.
Here, two diVerent Xow cytometry-based assays were
used to study tumor cell recognition. Target cell death was
determined with a cytotoxicity assay to study survival
kinetics of tumor cells up to 3 days. Cytolytic activation of
LRH-1-speciWc CTL was measured by levels of degranula-
tion. We demonstrated that LRH-1+ cell lines were suscep-
tible to LRH-1-speciWc CTL-mediated lysis. Especially,
brain tumor cell line DAOY was very eYciently lysed by
LRH-1-speciWc CTL. Lysis of melanoma cell line BLM
and RCC cell line SKRC33 was signiWcantly enhanced by
pre-incubation of target cells with inXammatory cytokines
IFN and TNF. P2X5 mRNA expression was not up-
regulated in response to inXammatory cytokines, as was
previously demonstrated for MiHA BCL2A1 in non-
hematopoietic cells [17]. However, cytokine stimulation
generally resulted in an increase of HLA-B7 and CD54
expression on tumor cells and higher levels of CD107a
expression on LRH-1-speciWc CTL. Therefore, these
results suggest that presence of inXammatory cytokines
results in an improved immunological synapse and better T
cell activation, which leads to increased target cell lysis.
InXammatory cytokines are known to play a role in anti-
tumor immunity [9]. The importance of an inXammatory
environment was previously demonstrated in a GVT study
in mice, in which secretion of IFN was required for
eradication of melanomas in vivo by MiHA-speciWc CTL.
Release of IFN resulted in inhibition of tumor angiogene-
sis and up-regulation of MHC class I expression on tumor
cells [18]. Importantly, we have demonstrated that P2X5 is
selectively expressed in hematopoietic cells [7] and a sub-
set of solid tumor cells, but not in GVHD target tissues
such as skin, liver and gut [7]. In addition, here we show
that cytokine treatment has an eVect on improved lysis of
solid tumor cells, whereas P2X5 expression remains unde-
tectable in keratinocytes and very low in skin-derived Wbro-
blasts in the presence of inXammatory cytokines.
Despite the lysis stimulating eVect of inXammatory cyto-
kines, partial lysis of RCC cell line SKRC18 could not be
enhanced by cytokine pre-incubation. SKRC18 cells could
only be eYciently lysed by LRH-1-speciWc CTL after
exogenous loading with LRH-1 peptide. This may indicate
that the P2X5 mRNA level, which was just above the
threshold of 0.4 (Table 1), was not suYcient for complete
lysis. In addition, SKRC 18 did not endogenously express
HLA-B7 and HLA-B7 expression could not be up-regu-
lated by cytokine pre-incubation. Another explanation may
be a defect in intracellular antigen processing. Resistance to
lysis due to defects in antigen-processing mechanisms was
previously demonstrated for HA-1+ solid tumor cell lines
[19]. Miyazaki et al. describe two HA-1H CTL-resistant
cell lines, of which one cell line became susceptible to
CTL-mediated lysis after cytokine treatment resulting in
restoration of TAP-gene expression. Defects in antigen pro-
cessing are important mechanisms for metastatic solid
tumors to escape from immune-control and may limit the
eVectiveness of immunotherapy [1].
In conclusion, our data show that the P2X5 gene, which
encodes MiHA LRH-1, is aberrantly expressed in a subset
of solid tumor cell lines and primary solid tumors. P2X5
expressing tumor types include RCC, melanoma, colorectal
carcinoma, brain tumor and breast tumor. Notably, LRH-1+
tumor cells are susceptible to LRH-1 CTL-mediated lysis
as shown by Xow cytometry-based cytotoxicity assays. This
susceptibility may be strongly enhanced by the presence of
inXammatory cytokines. Therefore, LRH-1 is an important
addition to the panel of hematopoietic-restricted MiHA that
are additionally expressed on solid tumor cells and can be
exploited for post-transplantation GVT-speciWc immuno-
therapy.
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